Innovent Biologics, Inc. (IVBXF)

Innovent Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	9,540	7,508	10,052	9,163	8,377	7,764
Short-Term Investments	-	375.56	867.53	-	-	-
Trading Asset Securities	-	-	50	3.21	638.21	357.3
Cash & Short-Term Investments	9,540	7,884	10,970	9,166	9,015	8,121
Cash Growth	10.56%	-28.13%	19.68%	1.67%	11.01%	72.97%
Accounts Receivable	1,722	1,184	1,006	575.27	968.41	475.38
Other Receivables	-	-	-	-	-	91.72
Receivables	1,722	1,184	1,006	575.27	975.91	575.2
Inventory	1,128	822.17	968.09	1,429	1,347	705.66
Other Current Assets	702.27	382.52	484.38	336.52	212.4	64.69
Total Current Assets	13,093	10,273	13,428	11,507	11,551	9,467
Property, Plant & Equipment	5,602	5,647	4,656	3,826	3,090	1,911
Long-Term Investments	3,132	3,901	794.09	630.2	417.26	12.94
Other Intangible Assets	1,388	307.48	27.79	30.05	19.75	-
Long-Term Deferred Charges	-	975.12	1,242	1,168	752.45	32.63
Other Long-Term Assets	379.25	499.02	478.64	427.63	412.07	410.15
Total Assets	23,594	21,603	20,627	17,589	16,244	11,835
Accounts Payable	432.29	357.68	372.55	325.62	195.05	120.62
Accrued Expenses	-	2,739	1,962	1,517	1,678	819.95
Current Portion of Long-Term Debt	1,109	405.1	1,195	888	365	255
Current Portion of Leases	6.09	8.83	25.18	26.39	22.27	16.16
Current Income Taxes Payable	61.9	75.84	194.05	3.3	60.59	-
Current Unearned Revenue	226.97	256.41	416.17	434.91	355.51	120.44
Other Current Liabilities	3,177	525.53	312.16	303.71	374.05	153.69
Total Current Liabilities	5,012	4,369	4,477	3,499	3,050	1,486
Long-Term Debt	2,263	2,412	2,327	2,215	2,023	925.18
Long-Term Leases	1.61	4.76	73.42	98.68	86.39	10.23
Long-Term Unearned Revenue	1,232	1,215	960.05	883.28	753.27	633.96
Other Long-Term Liabilities	663.13	483.82	262.71	162.31	0.34	-
Total Liabilities	9,172	8,485	8,100	6,859	5,913	3,055
Common Stock	0.11	0.11	0.11	0.11	0.1	0.1
Additional Paid-In Capital	-	27,723	27,324	24,706	22,494	18,541
Retained Earnings	-	-15,906	-15,768	-14,740	-12,560	-9,982
Comprehensive Income & Other	14,422	1,301	970.54	763.86	397.02	220.41
Total Common Equity	14,422	13,118	12,528	10,730	10,330	8,780
Shareholders' Equity	14,422	13,118	12,528	10,730	10,330	8,780
Total Liabilities & Equity	23,594	21,603	20,627	17,589	16,244	11,835
Total Debt	3,379	2,831	3,621	3,229	2,497	1,207
Net Cash (Debt)	6,161	5,053	7,349	5,938	6,518	6,915
Net Cash Growth	16.68%	-31.25%	23.77%	-8.91%	-5.73%	80.53%
Net Cash Per Share	3.70	3.10	4.71	3.98	4.48	5.10
Filing Date Shares Outstanding	1,643	1,638	1,622	1,534	1,462	1,403
Total Common Shares Outstanding	1,643	1,638	1,622	1,534	1,462	1,403
Working Capital	8,080	5,904	8,951	8,008	8,501	7,981
Book Value Per Share	8.78	8.01	7.72	6.99	7.07	6.26
Tangible Book Value	13,033	12,810	12,500	10,700	10,311	8,780
Tangible Book Value Per Share	7.93	7.82	7.71	6.97	7.05	6.26
Buildings	-	1,702	402.67	402.46	389.73	389.73
Machinery	-	3,133	4,795	2,523	1,420	1,183
Construction In Progress	-	1,339	6.18	1,139	1,293	287.66
Leasehold Improvements	-	426.63	121.82	107.66	106.85	76.76

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.